An outbreak of infant botulism tied to baby formula has expanded to include 51 infants across 19 states, federal officials said on Dec. 11.
The FDA “cannot rule out the possibility that contamination might have affected all ByHeart formula products,” officials said. “In response, CDC broadened the case definition to include any infant with botulism who was exposed to ByHeart formula at any time since the product’s release in March 2022.”
Officials identified 10 confirmed cases of botulism between December 2023 and July that meet the new case definition. They found none between March 2022 and December 2023.
Further recent cases have also been added to the total, including at least one case that started on Dec. 1.
Botulism occurs when a baby swallows spores from Clostridium botulinum, a bacterium. Samples of the ByHeart formula have tested positive for Clostridium botulinum.
Symptoms of botulism include difficulty swallowing and a lack of head control. All 51 infants with botulism were hospitalized. No infants have died as of yet.
Ohio is the new state reporting at least one case. The Ohio Department of Health has not released information on the matter.
The infant in Virginia began having symptoms on Nov. 12, a spokesperson for the Virginia Department of Health told The Epoch Times in an email.
People with the ByHeart formula are being told not to use it. They are encouraged to keep it in a safe place in case their infant develops symptoms of botulism. If no symptoms develop after one month, they should throw the formula away, the CDC says.
If symptoms do develop, medical care should be sought immediately.
Officials had been saying that the ByHeart formula was still being found in some stores despite the recall. In the latest update, officials said that they have not received any of those reports since Nov. 26.
The ByHeart infant formula recall also affects markets outside the United States, according to the FDA.
The agency said customer data provided by Amazon shows that a small quantity of recalled ByHeart infant formula was distributed to Argentina, Brazil, Brunei, Canada, Chile, China, Colombia, Ecuador, Egypt, Hong Kong, Israel, Jamaica, Japan, Republic of Korea, Peru, Philippines, Romania, Singapore, South Africa, Thailand, and the British Virgin Islands.
“Consumers worldwide should not use any ByHeart brand infant formula as all ByHeart products are included in this recall,” the FDA said.
Greece’s National Organization for Medicines (EOF) on Dec. 8 warned consumers not to use the ByHeart formula.







